Press Releases

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Press Releases

Feb 07, 2017
- Epidiolex ® NDA submission and launch preparation on track - - New Positive Phase 2 glioma data further demonstrates value of cannabinoid pipeline -  - Conference call today at 8:30 a.m. EST - LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the
Feb 07, 2017
- GW intends to advance oncology research and development efforts - LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its
Jan 30, 2017
LONDON, Jan. 30, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 February, 2017 its
Dec 05, 2016
- Posters Presented at American Epilepsy Society Annual Meeting - - New data includes key secondary efficacy endpoints - LONDON , Dec. 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and
Dec 05, 2016
- Three Positive Phase 3 Epidiolex clinical trials reported in 2016 - - NDA submission and launch preparation on track - - Conference call today at 8:00 a.m. EST - LONDON, Dec. 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical
Dec 01, 2016
-  Presentations include clinical results from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet Syndrome, as well as additional independent reports from Epidiolex Expanded Access Program sites  - -  GW will also unveil its new U.S. operating name, Greenwich Biosciences, Inc.   - LONDON, Dec.
Nov 30, 2016
LONDON, Nov. 30, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 December,
Nov 22, 2016
LONDON, Nov. 22, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin
Sep 26, 2016
- Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo -  - Today's data represents the third positive Phase 3 pivotal trial for Epidiolex reported in 2016 - - Data reinforce the potential of Epidiolex to be an important new medicine for patients

Ways to keep up to date with GW